immunogenicity and safety of a third dose and immune persistence of bbibp-corv vaccine in people with hiv infected

Conditions: COVID-19; HIV Infections

Summary: evaluation of immunogenicity, safety and persistence of the subjects with hiv infected received the third dose of inactivated covid-19 vaccine .

the subjects aged ≥18 years with hiv infected who have completed the schedule of two doses for 3 months recruited to receive a third dose of inactivated covid-19 vaccine. blood samples will be collected 3 times: before the third dose of vaccinatioin，28 days and 6 months after the third dose of vaccination. any local or systemic adverse events that occurred within 21 days after vaccination will be recorded.

Eligibility criteria:
inclusion criteria: * subjects aged ≥18. * body temperature \< 37.3 ° c confirmed by clinical examination before enrollment . * subjects who meet the diagnostic criteria for hiv infection and aids. * cd4+ count is less than 500/ul and more than 50/ul . * female subjects of reproductive age declare that they are not pregnant, have no birth plan in the first 3 months after enrollment, and have taken effective contraceptive measures in the first 2 weeks before enrollment. * able and willing to complete the entire study plan during the study follow-up period. * have the ability to understand the study procedures, voluntarily sign informed consent, and comply with the requirements of the clinical study protocol. * subjects participating in the past clinical trial have completed two doses of covid-19 vaccine and blood collection before and after immunization; exclusion criteria: * subjects were previously confirmed cases of covid-19 or asymptomatic infected persons. * being allergic to any component of vaccines (including excipients) . * subjects who have experienced severe allergic reactions to vaccines (e.g. acute anaphylaxis, urticaria, angoneeurotic edema, dyspnea, etc.). * having uncontrolled epilepsy and other progressive neurological disorders and a history of guillain-barre syndrome. * injection of non-specific immunoglobulin within 1 month before enrollment. * pregnant and lactating women. * the subjects are suffering from an acute illness; or thrombocytopenia patients with platelet count \< 20×10\^9/l within three days before inoculation, that is, patients at high risk of spontaneous bleeding. * acute hiv infection and opportunistic infection. * subjects with co-opportunistic infections who did not receive antiviral therapy. * subjects with cd4+ count less than 50/ul who have not received antiviral therapy. * hiv-infected subjects undergoing treatment with severe drug interactions and overlapping toxicity (kidney damage, liver damage, hematological problems, etc.). * patients with malignant tumors are undergoing chemotherapy and radiotherapy before and after surgery. * subjects who had vaccine-related adverse reactions after the second dose. * having high fever (axillary temperature ≥39.0℃) for three days after the second dose of inoculation, or severe allergic reaction. * having any adverse nervous system reaction after the second dose. * other subjects whose physical conditions, as determined by the investigator, are not suitable for inclusion in clinical studies.